Xeris Pharmaceuticals Inc (XERS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Xeris Pharmaceuticals Inc (XERS) has a cash flow conversion efficiency ratio of 0.759x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($9.87 Million) by net assets ($13.01 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Xeris Pharmaceuticals Inc (XERS) defensive interval to measure how many days the company can operate on defensive assets alone.
Xeris Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Xeris Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Xeris Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xeris Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sichuan Yimikang Environmental Tech Co Ltd
SHE:300249
|
0.053x |
|
Hagar hf
IC:HAGA
|
0.078x |
|
PROS Holdings Inc
NYSE:PRO
|
-0.149x |
|
Jutze Intelligent Technology Co Ltd
SHE:300802
|
0.021x |
|
Procter & Gamble Health Limited
NSE:PGHL
|
0.278x |
|
Aktis Oncology, Inc. Common stock
NASDAQ:AKTS
|
0.097x |
|
Suburban Propane Partners LP
NYSE:SPH
|
0.156x |
|
VIEL & Cie société anonyme
PA:VIL
|
0.111x |
Annual Cash Flow Conversion Efficiency for Xeris Pharmaceuticals Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Xeris Pharmaceuticals Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see XERS market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $13.69 Million | $28.63 Million | 2.091x | +67.46% |
| 2024-12-31 | $-29.61 Million | $-36.98 Million | 1.249x | -81.99% |
| 2023-12-31 | $-6.78 Million | $-47.02 Million | 6.934x | +404.50% |
| 2022-12-31 | $45.19 Million | $-102.89 Million | -2.277x | -126.98% |
| 2021-12-31 | $95.23 Million | $-95.53 Million | -1.003x | +82.02% |
| 2020-12-31 | $14.44 Million | $-80.56 Million | -5.580x | +22.80% |
| 2019-12-31 | $14.44 Million | $-104.35 Million | -7.228x | -868.48% |
| 2018-12-31 | $75.41 Million | $-56.28 Million | -0.746x | -275.00% |
| 2017-12-31 | $-57.83 Million | $-24.66 Million | 0.426x | -15.34% |
| 2016-12-31 | $-31.93 Million | $-16.09 Million | 0.504x | -- |
About Xeris Pharmaceuticals Inc
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related … Read more